PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

AI in Drug Discovery
Auto Draft
Auto Draft
Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Japan conducts world’s first iPS cell transplant for Parkinson’s

The team intends to develop a mass production system that enables the delivery of nerve cells derived from iPS cells all over the world.

A research team from Kyoto University, Japan has conducted the world’s first transplant of induced pluripotent stem (iPS) cells to treat Parkinson’s disease.

Nerve cells created from the artificially derived stem cells, known as iPS cells, were transplanted into the brain of the patient in a treatment researchers hope to develop into a method that can be covered under Japan’s health insurance system.

According to Jun Takahashi, a professor at the university’s Centre for iPS Cell Research and Application, the team intends to develop a mass production system that enables the delivery of nerve cells derived from iPS cells all over the world.

The clinical trial was carried out by the research centre and Kyoto University Hospital, with doctors verifying the transplant’s safety and effectiveness.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience